Inicio › Mieloma múltiple › Carolina del Norte › Durham
Ensayos clínicos de Mieloma múltiple en Durham, NC
36 estudios para Mieloma múltiple buscan participantes en centros de Durham y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1
- University of North Carolina /ID# 251203, Chapel Hill · A 10 mi de distancia
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ReclutandoFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · A 10 mi de distancia
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutandoFase 3
- Durham VAMC, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ReclutandoFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · A 10 mi de distancia
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · A 10 mi de distancia
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutandoFase 1
- Duke Cancer Center, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
ReclutandoEstudio observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · A 10 mi de distancia
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ReclutandoFase 1/2
- University Of North Carolina Health Care - Hillsborough Campus /ID# 272454, Hillsborough · A 13 mi de distancia
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- Duke University Hospital, Durham
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
ReclutandoFase 3
- Research Site, Durham
- Research Site, Chapel Hill · A 10 mi de distancia
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutandoFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · A 10 mi de distancia
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ReclutandoFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · A 10 mi de distancia
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- Duke University, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutandoFase 1/2
- Research Site, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 2
- University of North Carolina Medical Center, Chapel Hill · A 10 mi de distancia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Chapel Hill · A 10 mi de distancia
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ReclutandoFase 2
- Duke University Medical Center, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
ReclutandoFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · A 13 mi de distancia
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
ReclutandoFase 1/2
- GSK Investigational Site, Chapel Hill · A 10 mi de distancia
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Reclutando
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · A 10 mi de distancia
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutandoFase 3
- Research Site, Durham
- Research Site, Chapel Hill · A 10 mi de distancia
Selinexor and Backbone Treatments of Multiple Myeloma Patients
ReclutandoFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
ReclutandoFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · A 10 mi de distancia
Registry of Older Patients With Cancer
ReclutandoEstudio observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · A 10 mi de distancia
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
ReclutandoFase 2
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
ReclutandoFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · A 13 mi de distancia
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutandoFase 1
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ReclutandoFase 1
- University of North Carolina, Chapel Hill · A 10 mi de distancia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · A 10 mi de distancia
Registry for Adults With Plasma Cell Disorders (PCD's)
ReclutandoEstudio observacional
- North Carolina Cancer Hospital, Chapel Hill · A 10 mi de distancia
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Duke University Health System (DUHS), Durham
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY59 estudios
- Boston, MA45 estudios
- Atlanta, GA42 estudios
- Houston, TX39 estudios
- Nashville, TN31 estudios
- Denver, CO26 estudios
- St. Louis, MO26 estudios
- Rochester, MN25 estudios
- Columbus, OH25 estudios
- Chicago, IL24 estudios
- Milwaukee, WI23 estudios
- Baldwin Park, CA23 estudios
Otros estudios en Durham
- Cáncer de seno63 estudios
- Cáncer (todos los tipos)61 estudios
- Cáncer de pulmón de células no pequeñas42 estudios
- Leucemia mielógena aguda34 estudios
- Cáncer de pulmón33 estudios
- Cáncer metastásico33 estudios
- Cáncer de próstata32 estudios
- Cáncer del colon y del recto30 estudios
- Cáncer de ovario28 estudios
- Leucemia linfocítica crónica28 estudios
- Fallo cardíaco25 estudios
- Cáncer de páncreas24 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.